Vidya Ganapati Kattige

This inventor holds 14 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Glenmark Pharmaceuticals S.a., Ichnos Sciences Sa. Active years: 2012-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vidya Ganapati Kattige. Retrieved from https://idiyas.com/inventor/vidya-ganapati-kattige

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 2)

% Patents Active = 21.4

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 1 (Patent Applications = 9)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Maharashtra, IN (2012 - 2015)
Thane (W), IN (2013 - 2018)
Thane, IN (2012 - 2020)

Company Filing History:

13 out of 65

Glenmark Pharmaceuticals S.a.

Years Active: 2012-2020

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10821100 - Triazolone compounds as mPGES-1 inhibitors (2020-11-03),

2. 10391083 - Triazolone compounds as MPGES-1 inhibitors (2019-08-27),

3. 9949955 - Triazolone compounds as mPGES-1 inhibitors (2018-04-24),

4. 9439890 - Triazolone compounds as mPGES-1 inhibitors (2016-09-13),

5. 9186360 - Treatment of respiratory disorders using TRPA1 antagonists (2015-11-17),

6. 9096545 - Triazolone compounds as mPGES-1 inhibitors (2015-08-04),

7. 9006257 - Bicyclic compounds as mPGES-1 inhibitors (2015-04-14),

8. 8519149 - Tricyclic compounds as mPGES-1 inhibitors (2013-08-27),

9. 8492568 - Chromane derivatives as TRPV3 modulators (2013-07-23),

10. 8487121 - Chromane derivatives as TRPV3 modulators (2013-07-16),

11. 8349846 - Fused pyrimidine derivatives as TRPV3 modulators (2013-01-08),

12. 8344010 - Fused imidazole derivatives as TRPV3 antagonist (2013-01-01),

13. 8318928 - Fused imidazole carboxamides as TRPV3 modulators (2012-11-27),

14. 8119647 - Fused pyrimidineone compounds as TRPV3 modulators (2012-02-21),

Title: Inventor Profile: Vidya Ganapati Kattige

Introduction

Vidya Ganapati Kattige is a prominent inventor based in Thane, India. With a remarkable record of 14 patents, he has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for healthcare solutions.

Latest Patents

Among his latest inventions are triazolone compounds recognized as mPGES-1 inhibitors. These innovative compounds, including their pharmaceutically acceptable salts, serve as inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme. Their application is critical in treating pain and inflammation associated with a variety of diseases, including asthma, osteoarthritis, rheumatoid arthritis, and neurodegenerative disorders.

Career Highlights

Throughout his career, Vidya has been associated with renowned companies such as Glenmark Pharmaceuticals and Ichnos Sciences. His work in these organizations has influenced the development of therapeutic agents aimed at providing pain relief and managing inflammatory responses in patients.

Collaborations

Vidya has worked alongside notable peers, including Neelima Khairatkar-Joshi and Laxmikant Atmaram Gharat. These collaborations have facilitated the exchange of ideas and combined expertise that have further propelled advancements in their respective research fields.

Conclusion

In summary, Vidya Ganapati Kattige's innovative work and patents have made a significant impact on healthcare, particularly in pain management and inflammation treatment. His contributions are a testament to the power of innovation in transforming the pharmaceutical landscape, offering hope for better therapeutic options.

Profile summary based on public USPTO records.